Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Infectious Disease Information》 2017-06
Add to Favorite Get Latest Update

Progress in rescue therapy of tenofovir disoproxil fumarate for chronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil

SHAO Jin-man;TANG Xiao-feng;LIU Yan;XU Dong-ping;Peking University 302 Clinical Medical College;  
As the common anti-HBV drug,adefovir dipivoxil(ADV) has been recommended for the rescue therapy of lamivudine-resistant and treat-na?ve patients due to its less cost and no cross-resistance to lamivudine,telbivudine and entecavir.However,since ADV has a lower resistance gene barrier and lower clinical dose,patients with suboptimal virologic response to ADV accumulated during long-term antiviral treatment in clinic.Tenofovir disoproxil fumarate(TDF) has been recommended for the rescue therapy of the patients with suboptimal virologic response to ADV.TDF shows unequal efficacy in lamivudine-experienced and ADV-na?ve patients.And some studies in vitro reported that ADV resistance mutations reduce susceptibility to TDF.Whether TDF treatment can increase or aggravate the risk of nephrotoxicity for ADV-experienced patients should be concerned in clinical practice.This review aims to summarize progresses in rescue therapy of TDF for chronic HBV-infected patients with suboptimal virologic response to ADV,which will provide help for management of drug-resistant HBV infection.
【Fund】: 国家自然科学基金面上项目(81371852 81573676)
【CateGory Index】: R512.62
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved